Sabine C. Linn
YOU?
Author Swipe
View article: One size does not fit all: data-driven insights of patient-reported outcomes to tailor supportive care in breast cancer
One size does not fit all: data-driven insights of patient-reported outcomes to tailor supportive care in breast cancer Open
Purpose Supportive care resources are limited, requiring a strategic, tailored approach, especially with the growing population of breast cancer patients. We examined whether routinely collected Patient-Reported Outcome Measures (PROMs) ca…
View article: Worse prognosis for breast cancer diagnosed in advanced pregnancy and shortly postpartum: an update of the Dutch pregnancy-associated breast cancer cohort
Worse prognosis for breast cancer diagnosed in advanced pregnancy and shortly postpartum: an update of the Dutch pregnancy-associated breast cancer cohort Open
View article: Decision‐making in breast pathology reporting: the effect of clinical relevant thresholds
Decision‐making in breast pathology reporting: the effect of clinical relevant thresholds Open
Aims In breast cancer (BC) pathology reports, small differences around cut‐off values can impact staging and consequently, clinical decision‐making. Several pathology variables are not very exact, leaving room for interpretation by the pat…
View article: Supplementary Table S1 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)
Supplementary Table S1 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01) Open
Supplementary Table S1. Representativeness of study participants.
View article: Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers
Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers Open
View article: Data from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)
Data from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01) Open
Purpose:In hormone receptor–positive, HER2-negative, early-stage breast cancer, cyclin-dependent kinase 4 and 6 inhibition combined with endocrine therapy could represent a less toxic alternative to neoadjuvant chemotherapy (CT). The NEOLB…
View article: Supplementary Appendix S1 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)
Supplementary Appendix S1 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01) Open
Supplementary Appendix S1. Study protocol.
View article: Supplementary Table S2 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)
Supplementary Table S2 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01) Open
Supplementary Table S2. Pathological outcome (Ki67% and MP) to either neoadjuvant RL or CT.
View article: Supplementary Table S3 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)
Supplementary Table S3 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01) Open
Supplementary Table S3. Pathological outcome (Ki67% and MP) to either neoadjuvant RL or CT.
View article: Prognostication and treatment predictions for estrogen receptor positive early-stage breast cancer: incorporating the 70-gene signature into the PREDICT prognostication model
Prognostication and treatment predictions for estrogen receptor positive early-stage breast cancer: incorporating the 70-gene signature into the PREDICT prognostication model Open
View article: Breastfeeding after breast cancer in young <i>BRCA</i> carriers
Breastfeeding after breast cancer in young <i>BRCA</i> carriers Open
Background We investigated safety of breastfeeding after breast cancer in patients carrying germline BRCA pathogenic or likely pathogenic variants. Methods This was an international, multicenter, hospital-based, retrospective cohort study …
View article: Breast implant illness after reconstruction with silicone breast implants
Breast implant illness after reconstruction with silicone breast implants Open
Background “Breast implant illness” (BII) is a constellation of non-specific constitutional, rheumatologic, mental, and cognitive symptoms reported increasingly by women carrying silicone breast implants (SBIs). The impact of BII on the we…
View article: 416O Safety of having a subsequent pregnancy after a prior diagnosis of breast cancer during pregnancy (PrBC) in young BRCA carriers
416O Safety of having a subsequent pregnancy after a prior diagnosis of breast cancer during pregnancy (PrBC) in young BRCA carriers Open
View article: 268P Association between baseline body mass index and survival outcomes in BRCA carriers with breast cancer diagnosed at a young age: Results from an International cohort study
268P Association between baseline body mass index and survival outcomes in BRCA carriers with breast cancer diagnosed at a young age: Results from an International cohort study Open
View article: Three-year patient-reported outcomes of the BOOG 2013-08 RCT evaluating omission of sentinel lymph node biopsy in early-stage breast cancer patients treated with breast conserving surgery: Impact of personality traits on health-related quality of life
Three-year patient-reported outcomes of the BOOG 2013-08 RCT evaluating omission of sentinel lymph node biopsy in early-stage breast cancer patients treated with breast conserving surgery: Impact of personality traits on health-related quality of life Open
Background The non-inferiority randomized controlled trial BOOG 2013-08 investigates the oncological safety and impact on health-related quality of life (HRQoL) of sentinel lymph node biopsy (SNLB) omission in cT1–2 N0 breast cancer. The p…
View article: Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC
Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC Open
View article: Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer Open
Importance Subgroup definitions for possible deescalation of neoadjuvant cancer treatment are urgently needed in clinical practice. Objective To investigate the effect of BRCA1 and/or BRCA2 tumor pathogenic variants (tPVs) by comparing 2 d…
View article: Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer
Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer Open
View article: ECTIL: Label-efficient Computational Tumour Infiltrating Lymphocyte (TIL) assessment in breast cancer: Multicentre validation in 2,340 patients with breast cancer
ECTIL: Label-efficient Computational Tumour Infiltrating Lymphocyte (TIL) assessment in breast cancer: Multicentre validation in 2,340 patients with breast cancer Open
The level of tumour-infiltrating lymphocytes (TILs) is a prognostic factor for patients with (triple-negative) breast cancer (BC). Computational TIL assessment (CTA) has the potential to assist pathologists in this labour-intensive task, b…
View article: Bridging the Gap: A Mixed-Methods Study on Factors Influencing Breast Cancer Clinicians’ Decisions to Use Clinical Prediction Models
Bridging the Gap: A Mixed-Methods Study on Factors Influencing Breast Cancer Clinicians’ Decisions to Use Clinical Prediction Models Open
Background. Clinical prediction models provide tailored risk estimates that can help guide decisions in breast cancer care. Despite their potential, few models are widely used in clinical practice. We aimed to identify the factors influenc…
View article: The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy
The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy Open
The response of breast cancer to neoadjuvant chemotherapy (NAC) varies substantially, even when tumours belong to the same molecular or histological subtype1. Here we identify the oestrous cycle as an important contributor to th…
View article: Supplementary fig 3 from Ovarian Cancer–Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
Supplementary fig 3 from Ovarian Cancer–Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial Open
Supplemental Figure 3. Distance to the BRCA1 centroid. Distance to the BRCA1 mutated centroid is subtracted from the distance to the control centroid.
View article: Supplementary fig 1 from Ovarian Cancer–Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
Supplementary fig 1 from Ovarian Cancer–Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial Open
Supplemental Figure 1. CONSORT-like flow diagram of the AGO-TR1 trial. The sample for BRCA-like classification has been selected with the aim to enrich for germline (g) and somatic (s) mutation status.
View article: Supplementary fig 2 from Ovarian Cancer–Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
Supplementary fig 2 from Ovarian Cancer–Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial Open
Supplemental Figure 2. Error rate of the BRCA1-like ovarian cancer classifier at various thresholds of shrinkage.
View article: Data from Ovarian Cancer–Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
Data from Ovarian Cancer–Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial Open
Purpose:Previously, we developed breast cancer BRCA1-like and BRCA2-like copy-number profile shrunken centroid classifiers predictive for mutation status and response to therapy, targeting homologous recombination deficiency …
View article: Supplementary fig 4 from Ovarian Cancer–Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
Supplementary fig 4 from Ovarian Cancer–Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial Open
Supplemental Figure 4. Number of segments and variance of segments in misclassified and properly classified ovarian cancer samples with the BRCA1-like classifier.
View article: Supplementary Data from Ovarian Cancer–Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
Supplementary Data from Ovarian Cancer–Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial Open
Supplementary Methods
View article: Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial Open
View article: Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology Open
View article: High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers
High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers Open
Background and purpose: High-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients with stage III HER2-negative breast cancer with homologous recombination deficiency…